Suchergebnisse - "Voorhees, Peter M"

PubPharm (126)

1

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

enthalten in: Blood cancer journal | 2024

von Callander, N. | Silbermann, R. | Kaufman, J. | +33

2

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

enthalten in: Cancer | 2024

von Suvannasankha, A. | Bahlis, N. | Trudel, S. | +17

3

Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone : Patient-reported outcomes from GRIFFIN

enthalten in: American journal of hematology | 2024

von Silbermann, R. | Laubach, J. | Kaufman, J. | +23

4

Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium

enthalten in: Blood cancer journal | 2024

von Afrough, A. | Hashmi, H. | Hansen, D. | +27

5

Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

enthalten in: British journal of haematology | 2024

von Nooka, A. | Kaufman, J. | Rodriguez, C. | +16

6

Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)

enthalten in: Life (Basel, Switzerland) | 2024

von Ehsan, H. | Robinson, M. | Voorhees, P. | +8

7

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN) : final analysis of an open-label, randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2023

von Voorhees, P. | Sborov, D. | Laubach, J. | +25

CommentIn: Lancet Haematol. 2023 Oct;10(10):e788-e789. - PMID 37793762

8

Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myeloma

enthalten in: European journal of haematology | 2023

von Atrash, S. | Robinson, M. | Taneja, A. | +13

9

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma

enthalten in: Journal of the advanced practitioner in oncology | 2023

von Popat, R. | Lonial, S. | Voorhees, P. | +12

10

COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients

enthalten in: Vaccine: X | 2023

von Shahid, Z. | Patrick, A. | Wallander, M. | +11

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[13]